中文摘要：

制备了孔径（6.0±0.2）nm、孔容（0.94±0.03）cm3/g、比表面积（701.4±0.70）m2/g的SBA-15型介孔二氧化硅纳米粒,平均粒径为（920±120）nm,以其为载体负载艾塞那肽。所得SBA-15型介孔二氧化硅纳米粒因具有较大比表面积和比孔容,可提高载药量至（15.2±2.0）%。体外释放试验表明,该纳米粒在p H 7.4磷酸盐缓冲液中d1释出近35%,d14时缓慢释出40%。将艾塞那肽的水溶液和SBA-15型介孔二氧化硅纳米粒分别皮下注射给予SD大鼠。结果两组的t1/2为0.60和14.53 h,AUC0→t为1.71和8.60 ng·ml~（-1）·h,MRT为1.14和21.30 h,可见该载体可显著增加药物的半衰期和MRT,有望成为艾塞那肽皮下注射给药的理想载体。

英文摘要：

The SBA-15 mesoporous silica nanoparticles were prepared, which had an average particle size of（920±120） nm, a pore diameter of（6.0±0.2）nm, a pore volume of（0.94±0.03）cm3/g and a specifi c surface area of（701.4±0.70）m2/g. The exenatide-loaded nanoparticles were prepared with the prepared SBA-15 as carriers. Due to the big specifi c surface area and pore volume of SBA-15, the drug-loading was increased to（15.2±2.0）%. The results of in vitro release test showed that the release of exenatide from the nanoparticles was nearly 35% at d1 in p H 7.4 phosphate buffer, and slowly increased to 40% at d14. The exenatide solution and exenatide-loaded SBA-15 nanoparticles were subcutaneously injected to SD rats, respectively. The t1/2, AUC0→t and MRT of exenatide solution and exenatide-loaded SBA-15 nanoparticles were 0.60 and 14.53 h, 1.71 and 8.60 ng·ml~（-1）·h, 1.14 and 21.30 h, respectively. The results showed that SBA-15 could signifi cantly increase the drug half-life and MRT, which was expected to become a promising and ideal carrier of exenatide.